Inflammatory gene expression in monocytes of patients with schizophrenia:overlap and difference with bipolar disorder. A study in naturalistically treated patients by Drexhage, Roosmarijn C. et al.
  
 University of Groningen
Inflammatory gene expression in monocytes of patients with schizophrenia
Drexhage, Roosmarijn C.; van der Heul-Nieuwenhuijsen, Leonie; Padmos, Roos C.; van
Beveren, Nico; Cohen, Dan; Versnel, Marjan A.; Nolen, Willem A.; Drexhage, Hemmo A.
Published in:
International Journal of Neuropsychopharmacology
DOI:
10.1017/S1461145710000799
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2010
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Drexhage, R. C., van der Heul-Nieuwenhuijsen, L., Padmos, R. C., van Beveren, N., Cohen, D., Versnel,
M. A., ... Drexhage, H. A. (2010). Inflammatory gene expression in monocytes of patients with
schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients.
International Journal of Neuropsychopharmacology, 13(10), 1369-1381.
https://doi.org/10.1017/S1461145710000799
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Inﬂammatory gene expression in monocytes
of patients with schizophrenia: overlap and
diﬀerence with bipolar disorder. A study in
naturalistically treated patients
Roosmarijn C. Drexhage1, Leonie van der Heul-Nieuwenhuijsen1, Roos C. Padmos1,
Nico van Beveren2, Dan Cohen3,4, Marjan A. Versnel1, Willem A. Nolen5
and Hemmo A. Drexhage1
1 Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
2 Department of Psychiatry, Erasmus MC, Rotterdam, The Netherlands
3 Department of Epidemiology, University Medical Center, Groningen, The Netherlands
4 GGZ-NHN, Heerhugowaard, The Netherlands
5 Department of Psychiatry, University Medical Center, Groningen, The Netherlands
Abstract
Accumulating evidence indicates an activated inﬂammatory response system as a vulnerability factor for
schizophrenia (SZ) and bipolar disorder (BD). We aimed to detect a speciﬁc inﬂammatory monocyte gene
expression signature in SZ and compare such signature with our recently described inﬂammatory
monocyte gene signature in BD. A quantitative-polymerase chain reaction (Q-PCR) case-control gene
expression study was performed on monocytes of 27 SZ patients and compared to outcomes collected in
56 BD patients (all patients naturalistically treated). For Q-PCR we used nine ‘SZ speciﬁc genes’ (found in
whole genome analysis), the 19 BD signature genes (previously found by us) and six recently described
autoimmune diabetes inﬂammatory monocyte genes. Monocytes of SZ patients had (similar to those of
BD patients) a high inﬂammatory set point composed of three subsets of strongly correlating genes
characterized by diﬀerent sets of transcription/MAPK regulating factors. Subset 1A, characterized by
ATF3 and DUSP2, and subset 1B, characterized by EGR3 and MXD1, were shared between BD and SZ
patients (up-regulated in 67% and 51%, and 34% and 41%, respectively). Subset 2, characterized by
PTPN7 and NAB2 was up-regulated in the monocytes of 62% BD, but down-regulated in the monocytes of
48% of SZ patients. Our approach shows that monocytes of SZ and BD patients overlap, but also diﬀer
in inﬂammatory gene expression. Our approach opens new avenues for nosological classiﬁcations of
psychoses based on the inﬂammatory state of patients, enabling selection of those patients who might
beneﬁt from an anti-inﬂammatory treatment.
Received 8 February 2010 ; Reviewed 22 April 2010 ; Revised 11 May 2010 ; Accepted 8 June 2010 ;
First published online 15 July 2010
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Introduction
We (Padmos et al. 2008a) recently described a sensitive
quantitative polymerase chain reaction (Q-PCR) assay
system to detect the pro-inﬂammatory state of cir-
culating monocytes of naturastically treated patients
with bipolar disorder (BD) patients and detected in
the monocytes a coherent, mutually correlating set of
19 aberrantly expressed inﬂammatory genes (‘a gene
signature or ﬁngerprint ’), supporting the concept of
an activated inﬂammatory response system (IRS) in
mood disorders (Smith & Maes, 1995).
Since the concept of an activated IRS also extends to
schizophrenia (SZ) (Smith & Maes, 1995), we hy-
pothesized that the same or a similar abnormal in-
ﬂammatory gene ﬁngerprint could also be found in
monocytes of patients with SZ and we decided to test
Address for correspondence : R. C. Drexhage, M.D., Department of
Immunology, Erasmus MC, PO Box 2040, 3000CA Rotterdam,
The Netherlands.
Tel. : 0031 10 7044091 Fax : 0031 10 7044731
Email : r.drexhage@erasmusmc.nl




by University Library user
on 13 June 2018
for the 19 aberrantly expressed ‘bipolar signature
genes’ in the circulating monocytes of naturalistically
treated SZ patients. In addition, we searched for new
‘schizophrenia inﬂammatory genes’ using Aﬀymetrix
whole genome expression proﬁling (Aﬀymetrix, USA)
on monocytes of SZ patients and selected those genes
whichweremarkedly aberrantly expressed and clearly
involved in inﬂammation (yielding 15 ‘new’ genes, for
details see Results section).
Autoimmune diabetes, thyroiditis and gastritis
are about three times more prevalent in BD (Padmos
et al. 2004), whereas autoimmune thyrotoxicosis and
Sjogren’s disease are more prevalent in SZ (Eaton et al.
2006). Given our recently reported overlap in mono-
cyte gene expression signatures between BD and auto-
immune diabetes, we additionally included in our
analysis six ‘speciﬁc autoimmune diabetes signature
monocyte genes (Padmos et al. 2008b) ’ to be complete.
Thus, using Q-PCR, we validated for this report the
abnormal expression of 34 monocyte activation genes
in 27 patients with SZ [compared to monocytes of
32 age-/gender-matched healthy controls (HC)] and
56 patients with BD [42 patients of the previously re-
ported series (Padmos et al. 2008a) plus 14 new cases,




Patients with SZ were diagnosed according to the
DSM-IV criteria and recruited at the Department
of Psychiatry of the Erasmus Medical Center in
Rotterdam. All patients were in-patients. Patients
were diagnosed with SZ according to the DSM-IV cri-
teria after a Comprehensive Assesment of Symptoms
and History (CASH) interview (Andreasen et al. 1992)
and by consensus between two senior psychiatrists
who were blinded to the results. For patients with
symptoms for<6 months, a ﬁnal diagnosis was made
after 6 months to comply with the DSM-IV criterion.
All patients were acutely psychotic.
The SZ patients were almost all recent onset cases
and had a median duration of illness of only 0.3 yr
(range 0–3 yr). No cases suﬀered from any other
severe medical illness (including infections and al-
lergies), veriﬁedwith amedical history assessment and
routine laboratory testing (Hb, Ht, leukocyte count,
blood smear and kindney/liver function) on ad-
mission.
For Aﬀymetrix microarray analysis (searching
for aberrantly expressed genes in monocytes) two
monocyte pools of SZ patients were used. Each pool
was compared to a monocyte pool of age- and gender-
matched HC (pools were used for minimizing inter-
individual diﬀerences in mRNA expression and to
reduce costs for this expensive methodology). Patient
pool 1 consisted of four male cases, aged 22, 26, 27 and
20 yr, patient pool 2 consisted of three male cases, aged
17, 19 and 27 yr. Pools 1 and 2 were compared to two
HC pools of 2r2 males, aged between 22 and 26 yr.
For Q-PCR (verifying the found genes) 27 ad-
ditional SZ patients diagnosed according to DSM-IV
criteria were recruited at the Department of Psychiatry
of the Erasmus Medical Center in Rotterdam.
All but one of the patients received antipsychotic
medication at the time of blood draw; none of the
patients were drug naive. The demographics, duration
of illness and drug usage of the patients used in
Q-PCR are summarized in Table 1.
For the Q-PCR on SZ patients we used a control
group of 32 HC, who were age-/gender-matched to
the SZ patients. These were recruited from enrolling
laboratory staﬀ, medical staﬀ and medical students
(Table 1). The inclusion criteria for HC were an ab-
sence of any psychiatric and autoimmune disorder
and an absent history of these disorders in ﬁrst-degree
family members. HC had to be in self-professed good
health and free of any obvious medical illness for at
least 2 wk prior to blood draw, including acute infec-
tions and allergic reactions.
Patients with BD
In total, 56 outpatients with DSM-IV bipolar I or II
disorder were recruited from two studies, i.e. the
Dutch site of the former Stanley Foundation Bipolar
Network (SFBN), an international multi-centre re-
search programme described in detail previously
(Suppes et al. 2001) (n=19 patients) and from an on-
going Dutch twin study on BD described in detail by
Vonk et al. (2007) (n=37). Characteristics of BD
patients are given in Table 1. Diagnosis was also made
by means of the SCID. Present mood state was evalu-
ated via the Young Mania Rating Scale (YMRS) and
the Inventory for Depressive Symptomatology (IDS).
The BD patients did not have another severe medical
illness, veriﬁed by medical history assessment.
Since age and gender diﬀered between our BD and
SZ patients (Table 1) we compared outcomes of the BD
group to those of an extra group of 48 HC, who were
age-/gender-matched to the BD patients (Table 1). For
inclusion criteria for HC see earlier.
The Medical Ethical Review Committee of the
University Medical Center Utrecht (BD patients) and
the Medical Ethical Review Committee of the Erasmus
1370 R. C. Drexhage et al.
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MC Rotterdam (SZ patients) approved the studies.
Written informed consent was obtained from all par-
ticipants after a complete description of the study had
been given.
Laboratory methods
Blood collection and preparation
Blood (drawn in the morning) was collected in clotting
tubes for serum preparation (stored atx80 xC) and in
sodium-heparin tubes for immune cell preparation.
From the heparinized blood, peripheral blood mono-
nuclear cell (PBMC) suspensions were prepared in
the afternoon by low-density gradient centrifugation,
as previously described in detail (Knijﬀ et al. 2006),
within 8 h to avoid activation of the monocytes (ery-
throphagy). PBMCs were frozen in 10% dimethyl-
sulfoxide and stored in liquid nitrogen. This enabled
us to test patient and control immune cells in the same
series of experiments later.
Isolation of monocytes
CD14-positive monocytes were isolated from frozen
PBMCs by a magnetic cell sorting system (Miltenyi
Biotec, Germany). The purity of monocytes was>95%
(determined by morphological screening after Trypan
Blue staining and ﬂuorescent-activated cell sorting).
As previously reported, positive vs. negative selection
of immune cells did not inﬂuence gene expression
proﬁles (Lyons et al. 2007).
Aﬀymetrix whole genome gene expression proﬁling
RNA was isolated from puriﬁed monocytes using
RNAeasy columns according to the manufacturer’s
instructions (Qiagen, USA) and as previously de-
scribed (Staal et al. 2004). Fragmented cRNA was hy-
bridized to U95Av2 microarrays according to the
manufacturer’s instructions (Aﬀymetrix). For all ex-
periments, the 5k/3k ratios of GAPDH were f2
(usually 0.9–1.1).
Q-PCR
RNA was isolated from monocytes as described
earlier. To obtain cDNA for Q-PCR, 1 mg RNA was
reversed-transcribed using the cDNA high-capacity
cDNA Reverse Transcription kit (Applied Biosystems,
USA). Q-PCR was performed as previously described
in detail by Staal et al. (2004) and in the legend of
Table 2.
Statistics
Scanned microarray images were analysed using
Aﬀymetrix Microarray Suite 4.2 software. Further
analysis was performed using RMA software, modiﬁ-
cation by de Ridder (de Ridder et al. 2006) and
Ingenuity Systems (www.ingenuity.com) software.
Statistical analysis was performed using the SPSS 15.0
package for Windows (SPSS Inc., USA). Data were
tested for normal distribution using the Kolmogorov–
Smirnov test. Depending on the distribution pattern
and the total number of subjects, parametric (normal
distribution ando50 subjects) or non-parametric tests
Table 1. Characteristics of schizophrenia and bipolar patients





Group size 27 32
Age (yr)a 27 (17–59) 27 (21–47)
Gender
Male 22 (81%) 25 (78%)
Female 5 (19%) 7 (22%)
Duration illness (yr) 0.3 (0–3)
Age of onset 26 (17–58)
Medication
Typical antipsychotics 10 (37%)








Group size 56 48
Dutch twin study 37
Dutch site SFBN 19
Age (yr)a 42 (26–61) 42 (23–57)
Gender
Male 22 (39%) 20 (42%)
Female 34 (61%) 28 (58%)
Duration illness (yr) 16 (3.5–40)




Antipsychotics and lithium 5
Other 11
SFBN, Stanley Foundation Bipolar Network.
aMean (range).
b The bipolar patients did not have a history of drug or
alcohol dependency for at least 6 months ; this was not known
for the schizophrenia patients.
c Data on 42 of these 56 patients have been published
previously (Padmos et al. 2008a).
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Table 2. Q-PCR analysis of monocytes of bipolar (BD) patients [n=56, 42 from a
previous study (Padmos et al. 2008a) plus 14 new cases) and schizophrenia (SZ)
patients (n=27) compared to healthy control (HC) values (HC SZ: n=32 ; HC BD:
n=48), set at 1-fold.
Schizophrenia Bipolar disorder
Genes selected by whole genome screening in this study in schizophrenia
EGR3 5.36a <0.01c 2.52 0.16
MXD1 1.49 <0.01 1.43 0.06
MAFF 5.10 <0.01 2.95 0.01
F3 5.56 <0.01 1.87 0.02
SERPINB2 1.84 <0.01 1.10 0.06
THBS 4.31 <0.01 2.02 0.05
EREG 7.36 <0.01 2.31 <0.01
CXCL3 3.99 <0.01 3.33 <0.01
RGC32 0.85b 0.07 2.61 <0.01
Genes selected in a previous study on bipolar patients (Padmos et al. 2008a)
DUSP2 5.36 <0.01 4.96 <0.01
ATF3 3.50 <0.01 3.55 <0.01
MAPK6 1.21 <0.01 1.80 <0.01
PDE4B 3.91 <0.01 3.00 <0.01
IL6 7.89 <0.01 5.39 <0.01
IL1B 9.20 <0.01 6.45 <0.01
TNF 3.91 <0.01 1.87 <0.01
TNFAIP3 3.22 <0.01 2.31 <0.01
BCL2A1 2.39 <0.01 3.30 <0.01
PTX3 2.51 <0.01 2.63 <0.01
PTGS2 4.34 <0.01 3.20 <0.01
CCL7 1.12 <0.01 8.47 <0.01
CDC42 1.49 <0.01 1.99 <0.01
CCL20 23.53 <0.01 10.63 <0.01
CXCL2 3.76 <0.01 5.31 <0.01
CCL2 1.60 <0.01 3.83 <0.01
CCR2 0.85 0.53 0.62 0.10
NAB2 0.76 0.21 2.58 <0.01
EMP1 0.97 0.88 2.19 <0.01
Genes selected in previous study on autoimmune diabetes (Padmos et al. 2008b)
PTPN7 0.78 0.04 2.04 <0.01
CD9 1.49 0.59 2.16 <0.01
STX-1A 0.64 0.22 3.04 <0.01
DHRS3 1.08 0.51 1.87 0.08
FABP5 1.08 0.75 1.21 0.09
HSPA1A 1.06 0.93 0.79 0.40
Q-PCR was performed with Taqman Universal PCR mastermix (Applied
Biosystems, USA). All Taqman probes and consensus primers were pre-formulated
and designed by Applied Biosystems (Assays on Demand, see Supplementary
Table 1, online). PCR conditions were 2 min at 50 xC, 10 min at 95 xC, followed by
40 cycles of 15 s at 95 xC, and ﬁnally 1 min at 60 xC. PCR ampliﬁcation of the reference
gene ABL was performed for each sample to allow normalization between the
samples. ABL was chosen as a reference gene because it was previously shown that
ABL was the most consistently expressed reference gene in haematopoietic cells
(Beillard et al. 2003). The quantitative value obtained from Q-PCR is a cycle threshold
(Ct). The fold change values between diﬀerent groups were determined from
normalized Ct values (Ct gene – Ct housekeeping gene), by the DDCt method
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(skewed distribution or <50 subjects) were used.
Bonferroni correction for multiple testing was used for
the Aﬀymetrix data (since this was a non-hypothesis-
driven approach). Correction for multiple testing was
not used for the analysis of the Q-PCR data, because
we focused on the eﬀect of speciﬁc genes found in
the Aﬀymetrix analysis. The speciﬁc tests used are
mentioned in the table notes and ﬁgure legends.
Results
Whole genome expression proﬁling of potential
inﬂammatory biomarker genes in monocytes of
SZ patients
Aﬀymetrix microarray analysis was performed to
search for aberrantly expressed genes in monocytes on
two monocyte pools of naturalistically treated SZ
patients. Each pool was compared to a monocyte pool
of age- and gender-matched HC (pools were used
for minimizing inter-individual diﬀerences in mRNA
expression and to reduce costs for this expensive
methodology). All raw data obtained by Aﬀymetrix
analysis are available as MIAMExpress submission
(http://www.ebi.ac.uk/miamexpress/).
We analysed the data using a modiﬁed RMA
analysis (de Ridder et al. 2006) and considered for
Ingenuity analysis genes which were >2-fold statisti-
cally diﬀerentially expressed (p<0.01, corrected for
multiple testing) between SZ patients and HC. This
resulted in 298 discriminating genes (185 up-regulated
and 113 down-regulated). Major pathways found in
Ingenuity analysis were pathways involved in in-
ﬂammatory and immune mediated disease. To select
for genes which could serve as potential biomarkers
for the ‘schizophrenia inﬂammatory condition’, we
took the top genes from the up and down list, which
were statistically >3.5-fold signiﬁcantly diﬀerentially
expressed between SZ and HC with the purpose of
only identifying strongly discriminating genes. This
resulted in 22 overexpressed genes. None of the genes
was >3.5-fold lower expressed [the ﬁrst gene of the
list of the lower-expressed genes was CCR2, which
was 2.9-fold lower expressed, but this gene had
already been selected in our previous bipolar study
(Padmos et al. 2008a). Because we were searching for
regulators and biomarkers of inﬂammation, out of
these 22 aberrantly expressed genes we selected only
genes clearly involved in inﬂammation. This resulted
in 14 selected aberrantly expressed genes for SZ, and it
is of note that ﬁve of these genes had previously been
found overexpressed in BD patients, i.e. PDE4B, IL1,
PTGS2/COX2, CCL20 and CXCL2 (Padmos et al.
2008a), pointing to a strong overlap of inﬂammatory
set points between monocytes of BD and SZ. In sum,
nine new ‘schizophrenia speciﬁc’ up-regulated genes
(MXD1, F3, MAFF, EGR3, THBS, SERPINB2/PAI-2,
RGC32, EREG, CXCL3) were ﬁnally selected and we
included these nine new genes together with the 19
aberrantly expressed ‘bipolar signature genes’ and the
six ‘autoimmune diabetes signature genes’ in the
validating Q-PCR analysis of the 27 SZ patients, 56 BD
patients [42 patients of the previously reported study
of Padmos et al. (2008a) plus 14 new cases] and their 32
and 48 matched HC respectively.
Q-PCR analysis of monocytes of SZ and BD patients
Table 2 (and Supplementary Table 1, available online)
show that of the 34 genes tested, the mRNA expression
levels of 25 genes were signiﬁcantly diﬀerent (p<0.05
by ANCOVA, corrected for age and gender) in the
monocytes of the 27 SZ patients compared to HC,
while in the monocytes of the 56 BD patients 27 genes
were signiﬁcantly diﬀerently expressed. Data obtained
in Q-PCR on the mRNA expression levels of the
various genes in the patient groups correlated very
strongly to those obtained in the above-described
Aﬀymetrix analysis (SZ: r=0.708 ; BD: r=0.663,
Spearman’s r).
(2xDDCt, User Bulletin 2, Applied Biosystems, USA). To correct for inter-assay variance, we set the mean of the studied genes
found in the healthy control groups in the same assay for each gene to 1 (SDCt : HC=0, 2x0=1). The fold change values of the
genes in patients’ monocytes were expressed relative to this set mean of 1.
Data are expressed relative to this HC value. HC SCZ: n=32 ; HC BD: n=48.
a Values>1 : patients have a higher expression than control group.
b Values<1 : patients have a lower expression than control group.
c P tested by univariate ANCOVA vs. control subjects ; age and gender are included in this model.
Purity of monocytes was>90% (as determined by morphology on each sample) and>92% as determined by ﬂuorescent
assisted cell sorting analysis. Yield of monocytes was 28% (¡10%) in the patient groups group and 21% (¡8%) for the HC
group (n.s.) of the Ficoll-isolated peripheral blood mononuclear cells.
The DCt values are available in Supplementary Table 1 (online).
(Table 2 footnote continued)
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Fig. 1.Heat map of gene correlation. Correlation of expression of the various genes ; data represent Spearman’s correlation coeﬃcients, tested on the relative mRNA expression of the
genes in 83 individuals : 56 bipolar patients, 27 schizophrenia patients. Signiﬁcant positive correlations (p<0.05) are given by the red scale (darkest red are correlations>0.60),
signiﬁcant negative correlations are given by the green scale. White ﬁelds are not signiﬁcant. (a) The correlations of all tested genes to each other are shown. (b) Three sets of MAPK
regulators/transcription factors have been extracted from panel (a), namely DUSP2/ATF3,MXD1/EGR3 and PTPN7/NAB2 and correlations to the other genes are shown. Note that
(1) DUSP2/ATF3 correlate strongest to sub-cluster 1A genes (and weaker to the other subsets of genes), (2)MXD1/EGR3 correlates strongest to sub-cluster 1B genes and many of the
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There were no diﬀerences in mRNA gene ex-
pression for the diﬀerent groups of HC (Supplemen-
tary Table 1).
The aberrantly expressed genes were mostly shared
between the two disorders but also in part not shared.
Of the nine ‘schizophrenia speciﬁc’ genes, eight were
conﬁrmed by Q-PCR in SZ (RGC32 appeared not to be
higher expressed) ; while in BD patients ﬁve of these
genes were signiﬁcantly higher expressed (MAFF, F3,
EREG, CXCL3, RGC32).
Of the 19 ‘bipolar signature genes’ 16 were statisti-
cally signiﬁcantly up-regulated in SZ, while for three
genes statistical signiﬁcance was not reached (CCR2,
NAB2, EMP1). Conﬁrming our previous data, we
found almost all 19 ‘bipolar signature genes’ (apart
from CCR2) statistically signiﬁcantly overexpressed in
this extended set of BD patients.
Of the six ‘autoimmune diabetes signature genes’,
ﬁve were not aberrantly expressed in SZ, while PTPN7
was statistically signiﬁcantly down-regulated.
Interestingly, in the BD sample 3/6 genes were up-
regulated, including PTPN7.
Cluster analysis and identiﬁcation of sub-clusters in
the pro-inﬂammatory signature
To study their mutually inter-dependent state in
expression, we subsequently performed a cluster
analysis on the Q-PCR data. The heat map and
dendrograms of this analysis are given in Fig. 1a. In
sum, expression levels of virtually all genes correlated
to each other, yet two sub-clusters of mutually very
strongly correlating genes (correlation coeﬃcient
>0.60) could clearly be identiﬁed (two major red
blocks in the ﬁgure), each predominantly correlating
to a diﬀerent set of transcription/MAPK regulating
factors, i.e. ATF3/DUSP2 and PTPN7/NAB2, respect-
ively. These two sets of transcription factors were
mutually, but not strongly, correlated (Fig. 1b).
The ﬁrst sub-cluster correlating to ATF3 andDUSP2
consisted predominantly of various well-known in-
ﬂammatory compounds, such as the pro-inﬂamma-
tory cytokines IL1, IL6 and TNF, the inﬂammatory
compounds PTGS2/COX2 and PTX3, various inﬂam-
matory chemokines (CCL20, CXCL2, CXCL3) and
PDE4B (Fig. 1b).
The second sub-cluster (further indicated as sub-
cluster 2) correlating to PTPN7 and NAB2 consisted
predominantly of various adhesion/motility/chemo-
tactic factors, such as EMP1, CDC42, CCL2 and CCL7
(Fig. 1b).
In careful analysis (Fig. 1b, Supplementary Fig. 1,
online), sub-cluster 1 contained a further sub-cluster
Table 3. Fold change values of all genes grouped by cluster
Schizophrenia Bipolar disorder
Cluster 1A
DUSP2 5.36 <0.01 4.96 <0.01
ATF3 3.50 <0.01 3.55 <0.01
PDE4B 3.91 <0.01 3.00 <0.01
IL6 7.89 <0.01 5.39 <0.01
1L1B 9.20 <0.01 6.45 <0.01
TNF 3.91 <0.01 1.87 <0.01
TNFAIP3 3.22 <0.01 2.31 <0.01
BCL2A1 2.39 <0.01 3.30 <0.01
PTX3 2.51 <0.01 2.63 <0.01
PTGS2 4.34 <0.01 3.20 <0.01
CCL20 23.53 <0.01 10.63 <0.01
CXCL2 3.76 <0.01 5.31 <0.01
EREG 7.36 <0.01 2.31 <0.01
CXCL3 3.99 <0.01 3.33 <0.01
Cluster 1B
MXD1 1.49 <0.01 1.43 0.06
F3 5.56 <0.01 1.87 0.02
MAFF 5.10 <0.01 2.95 0.01
EGR 3 5.36 <0.01 2.52 0.16
THBS 4.31 <0.01 2.02 0.05
PAI-2 1.84 <0.01 1.10 0.06
RGC32 0.85 0.07 2.61 <0.01
Cluster 2
hePTP 0.78 0.04 2.04 <0.01
NAB2 0.76 0.21 2.58 <0.01
MAPK6 1.21 <0.01 1.80 <0.01
EMP1 0.97 0.88 2.19 <0.01
STX-1A 0.64 0.22 3.04 <0.01
DHRS3 1.08 0.51 1.87 0.08
CCL2 1.60 <0.01 3.83 <0.01
CCL7 1.12 <0.01 8.47 <0.01
CDC42 1.49 <0.01 1.99 <0.01
FABP5 1.08 0.75 1.21 0.09
CD9 1.49 0.59 2.16 <0.01
HSPA1A 1.06 0.93 0.79 0.40
CCR2 0.85 0.53 0.62 0.10
The quantitative value obtained from Q-PCR is a cycle
threshold (Ct). The fold change values between diﬀerent
groups were determined from the normalized Ct values
(Ct gene – Ct housekeeping gene), via the DD Ct method
(User Bulletin, Applied Biosystems). The fold change of HC
was set to 1.
Data are expressed relative to this HC value. HC SCZ:
n=32 ; HC BD: n=48.
Values>1 : patients have a higher expression than control
group. Boxes indicate signiﬁcantly up-regulated.
Values<1 : patients have a lower expression than
control group. Grey shaded box indicates signiﬁcantly
down-regulated.
p tested by univariate ANCOVA vs. control subjects ; age
and gender are included in this model.
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consisting of the transcription factors EGR3 and
MXD1, which were mutually strongly correlating to
the transcription factors MAFF and F3, but more
weakly to ATF3/DUSP2 and PTPN7/NAB2 (Fig. 1b,
this sub-sub cluster is further indicated as sub-cluster
1B, the other remaining set being sub-cluster 1A).
The expression of the three sub-clusters in SZ and BD
Tables 3 and 4 show that sub-cluster 1A is expressed in
the monocytes of both SZ and BD patients. If one de-
ﬁnes sub-cluster 1A positivity as positive for ATF3
and/orDUSP2 (i.e. an expression level higher than the
mean¡1 S.D. of the HC values) 67% of BD and 52% of
SZ patients are positive vs. 24% and 24% of their
matched HC, respectively (Table 4).
With regard to sub-cluster 1B, Tables 3 and 4 show
that SZ patients and BD patients are positive, but in
lower proportions. Using the same type of deﬁnition
as for sub-cluster 1A (but now for EGR3 and/or
MXD1), it appeared that SZ patients were signiﬁcantly
positive for 41% vs. 34% of BD patients (vs. 13% and
22% of their HC, Table 4).
With regard to sub-cluster 2, Tables 3 and 4 show
that only BD patients show an up-regulation of these
genes. Interestingly, SZ patients show a signiﬁcant
down-regulation of two transcription factors belong-
ing to this sub-cluster, i.e. PTPN7 and NAB2 (signiﬁ-
cant for PTPN7), while MAPK6 is up-regulated (yet
not to the same extent as in BD). It is noteworthy that
the adhesion/motility factors EMP1 and STX1A are
down-regulated too. If one deﬁnes sub-cluster 2 posi-
tivity as positive for PTPN7 and/or NAB2 (see above
for deﬁnition), even a signiﬁcantly reduced expression
in SZ vs. HC can be seen (7% vs. 21%), while in BD
there is a signiﬁcant increased expression (62% vs.
32%) (Table 4). Conversely, if sub-cluster 2 is deﬁned
as a ‘negative’ signature (Table 4, last column) a
higher proportion of SZ patients is positive for such
reduced expression (48%).
Relation of monocyte inﬂammatory gene expression
to medication use, disease duration and disease
activity
Medication use
To test for the inﬂuence of lithium and antipsychotics,
we turned to the group of BD patients, since almost all
patients with SZ were on antipsychotics ; only one was
not, but had used an antipsychotic in the past. Of the
56 BD patients, 32 were on lithium, eight were on anti-
psychotics, ﬁve used both and at the time of blood
draw 11 were not on lithium or an antipsychotic but
had used this medication in the past (>6 months ago).
Table 5a shows the eﬀects of the medications in this
BD group. Use of lithium and antipsychotics either
alone or in combination resulted in a signiﬁcant de-
crease of PDE4B, but not of other genes (although
there was a near signiﬁcant trend for a decreasing ef-
fect of lithium and antipsychotics on other important
signature 1A genes such as IL1 and TNF).
With regard to sub-cluster 2 genes there was a
near signiﬁcant increasing trend of the use of anti-
psychotics in BD patients on genes such as PTPN7,
NAB2 and STX1A (data not shown). This increasing
eﬀect of antipsychotics on sub-cluster 2 genes was also
reﬂected in the ‘ lifetime cumulative antipsychotic
drug usage in haloperidol equivalents’ which
positively and signiﬁcantly correlated to important
sub-cluster 2 genes as PTPN7 (r=0.55), HSPA1A
(r=0.61) and EMP1 (r=0.62).
Table 4. The prevalence of sub-clusters in bipolar patients, schizophrenia patients and healthy controls









Schizophrenia 52% (14/27)a 41% (11/27)a 7% (2/27)b 48% (13/27)ab
Healthy controls 24% (7/29) 13% (4/30) 21% (6/29) 21% (6/29)
Bipolar disorder 67% (26/39)a 34% (12/36) 62% (24/39)a 5% (2/39)a
Healthy controls 24% (10/41) 22% (8/36) 32% (13/41) 25% (10/40)
a p<0.05 vs. healthy controls.
b p<0.05 vs. bipolar disorder.
Positive is deﬁned as an mRNA expression>1 S.D. away of the mean level found in the healthy controls. Signature is deﬁned on
the transcription factors positive. p values are obtained from x2 test.
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Duration of illness
The patients with SZ were in general recent onset
cases and had a median duration of illness of only
y2 months (Table 1). Eﬀects of duration of illness
were not noticeable.
The BD patients had a median duration of illness of
16 yr (range 3.5–40 yr, Table 1) ; in this latter group
there was a weak, although signiﬁcant correlation be-
tween disease duration and the expression of some of
the signature genes : we found a weak positive cor-
relation for IL6, PTX3, CCL2 and EMP1 (r=0.30–0.40)
and a weak negative correlation for HSPA1A (r=
x0.30), indicating a slightly stronger expression of
part of the inﬂammatory ﬁngerprint over years.
Disease quality and severity
In the SZ patients disease quality and severity (as ex-
pressed in the various PANSS scales) did not correlate
to any of the various gene expression levels.
With regard to BD, we previously reported
(Padmos et al. 2008a) that the actual mood status of the
patients tested was to some extent related to the in-
ﬂammatory gene expression. During a manic episode,
the mRNA expression of 2/19 genes were signiﬁcantly
increased in monocytes of manic vs. euthymic BD
patients ; during depressive episodes 6/19 genes. In
the presently extended series of 56 BD patients we
largely conﬁrmed this observation and now found
1/34 genes during mania (n=7 patients) and 6/34
genes during depression (n=9 patients) raised [in
comparison to euthymic patients (n=40 patients),
Table 5b]. Interestingly these were all cluster 2 genes.
Although active disease thus is related to a higher ex-
pression of many of the cluster 2 signature genes (in
depressive phases more than in manic phases), it must
be noted that virtually all of the cluster 2 genes were
still signiﬁcantly higher in euthymic BD patients
compared to HC.
Inﬂammatory gene expression at the protein level
We previously reported on the IL1b, IL6, TNFa, CCL7
and CCL2 levels in the serum of these sets of BD and
SZ patients (Drexhage et al. 2008; Padmos et al. 2008a),
and found that only IL1b was increased in BD (com-
pared to HC), while IL1b, IL6, TNFa and CCL2were all
increased in SZ patients (compared to HC).
With regard to PTX3, we were able in this study to
measure serum levels and found these increased in BD
and SZ patients (Fig. 2). The ﬁgure shows that in BD
Table 5. Correlations of aberrant gene expression
(a) With medication use in bipolar patients
Medication Genes p B 95% CI
Lithium PDE4B 0.002 down x12.302 x4.736 tox19.867
Antipsychotics PDE4B 0.002 down x16.613 x6.555 tox26.671
Both PDE4B 0.005 down x17.142 x5.468 tox28.817
Linear regression with lithium, antipsychotics and both medications were included in the model. The values of patients on the
indicated drug are set to 1 in the model. B, Regression coeﬃcient.
(b) With the mood status of bipolar patients
Genes
Depressive (n=9) vs. Euthymic (n=40) Manic (n=7) vs. Euthymic (n=40)
B 95% CI p B 95% CI p
CCL2 105.24 37.49–172.98 0.003 22.93 x44.81 to 90.68 0.500
STX1A 36.59 13.52–59.69 0.002 8.77 x14.30 to 31.83 0.449
DHRS 9.91 3.00–16.83 0.006 x0.28 x6.78 to 6.22 0.930
PTPN7 3.82 1.08–6.56 0.007 2.25 x0.49 to 4.99 0.106
MAPK6 2.76 0.83–4.69 0.006 2.29 0.36 to 4.22 0.021
EMP1 12.72 7.31–18.12 0.001 3.83 x1.58 to 9.24 0.161
Determination of the inﬂuence of mood on mRNA expression of molecules via ANCOVA analysis.
The values of patients with a euthymic mood are set to 1. B, Regression coeﬃcient.
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and SZ PTX3 serum levels are signiﬁcantly raised over
HC levels, i.e. y2.5-fold in BD and y1.5-fold in SZ.
When we correlated serum PTX3 protein levels to
monocyte gene expression levels we found a signiﬁ-
cant positive correlation, although weakly (r=0.184,
p=0.05, Spearman’s correlation), indicating that
factors other than monocyte gene expression also de-
termine serum PTX3 levels.
Discussion
The outcomes of our study show that circulating
monocytes are set at a high inﬂammatory gene ex-
pression set-point in both SZ and BD. On the protein
level these high gene expression set-points were
(weakly, but signiﬁcantly) reﬂected in high serum
levels of pro-inﬂammatory cytokines and compounds.
Although monocytes of BD and SZ patients clearly
overlapped in signature gene expression sets 1A and
1B, they also diﬀered with regard to signature gene
expression set 2. We found the MAP kinase-regulating
factors PTPN7 and NAB2 up-regulated in monocytes
of BD patients, but down-regulated in monocytes of
SZ patients. Our immune biomarker approach thus
made a distinction between BD and SZ possible.
Although thus supporting the dichotomy between BD
and SZ as introduced in 1899 by Kraepelin (1899), our
immune data also lend support to the recently ex-
pressed view by geneticists (Bramon & Sham, 2001;
Lichtenstein et al. 2009 ; Owen & Craddock, 2009;
Thomson et al. 2005) that BD and SZ are strongly
overlapping entities sharing the same vulnerability
genes, since we found monocytes of considerable
proportions of BD and SZ patients to share an up-
regulated pro-inﬂammatory gene sub-cluster 1A,
composed mainly of a network of well known pro-
inﬂammatory cytokines and compounds such as IL1,
IL6, TNF, PTGS2/COX2 and PTX3, many of which
have previously been found up-regulated mainly at
the protein level in mood disorders and SZ (Drexhage
et al. 2008 ; Padmos et al. 2008a).
In addition, we found monocytes, particularly of SZ
patients, to be set at a further and higher inﬂammatory
set-point, due in particular to an extra up-regulation of
the transcription factors/regulators EGR3, MXD1,
MAFF and F3. These transcription factors/regulators
aremainly involved in proliferation and diﬀerentiation
of monocytes, but also play a role in the regulation
of the inﬂammatory set-point of monocytes/
macrophages (Ayer & Eisenman, 1993 ; Blank, 2008;
Carter & Tourtellotte, 2007 ; Collins et al. 2008; Hurlin
& Huang, 2006 ; Motohashi et al. 1997). Our data,
which show a strong correlation of EGR3, MXD1,
MAFF and F3 to the inﬂammatory cytokines and
compounds to which ATF3 and DUSP2 were also
correlating, supports such a view of involvement of
these transcription factors in inﬂammation. Interest-
ingly, the expression of EGR3, MXD1, MAFF and F3
were particularly correlated to the up-regulation of
the adipogenic and vascular pathology factors THBS
and SERPINB2/PAI-2, and it is here of note that the
incidence of the metabolic syndrome is increased in
BD and SZ (Birkenaes et al. 2007).
Our study has limitations. First, patients with SZ
were predominantly male and young in the 20-yr age
group and virtually all had recent onset disease and
were on antipsychotic medication ; the BD patients
were predominantly female and in the 40-yr age
group, had mainly longstanding disease and many
used lithium and/or antipsychotics. All patients were
naturalistically treated and none of our patients was
‘treatment naive’. It could be argued that age and













Bipolar disorder Schizophrenia Healthy control
p < 0.01
p < 0.01
Fig. 2. Serum PTX3 levels in bipolar disorder (BD) patients,
schizophrenia (SZ) patients and healthy controls (HC).
Box plots of PTX3 are given. The serum PTX3 level was
determined via an in-house ELISA (M7M) on the serum of
58 BD patients, 181 SZ patients and 188 HC, some of whom
were also used for Q-PCR according to the manufacturer’s
protocol (for patient details see Drexhage et al. 2008). The box
indicates the lower and upper quartiles. The line within the
box represents the median. The whiskers extend to the 2.5
and 97.5 percentiles. The outliers are characterized by the
ﬁlled dots. ANCOVA was used for statistical evaluation.
Age and gender were included in the statistical model, other
confounding factors such as adiposity could, however, not be
investigated, since we were not informed of the adiposity in
the majority of the cases tested here. The ﬁgure shows that in
BD and SZ, PTX3 serum levels are signiﬁcantly raised over
HC levels, i.e.y2.5-fold in BD andy1.5-fold in SZ.
Correlating serum PTX3 protein levels to monocyte gene
expression levels we found a signiﬁcant positive correlation,
although only weakly (r=0.184, p=0.05, Spearman’s
correlation).
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and BD and that medication is the causal factor for the
high inﬂammatory gene expression level in monocytes
of psychiatric patients.
With regard to age and gender, it must be noted that
we compared the patient ﬁndings with those of age-
and gender-matched control groups and that the
monocyte inﬂammatory state in these control groups
of diﬀerent age and gender did not diﬀer (Supple-
mentary Table 1).
With regard to the eﬀects of medication it must be
noted that eﬀects of lithium and antipsychotics are
generally anti-inﬂammatory in character (Drzyzga
et al. 2006 ; Pollmacher et al. 2000 ; Rybakowski, 2000)
and the data presented here, as well as our previous
data (Padmos et al. 2008a), support such an immune
suppressive action and show that, if anything, these
medications do not induce but rather correct the ab-
normal inﬂammatory set-point of patient monocytes
(see Table 5a). However, we can not totally rule out an
important eﬀect of illicit drugs on the induction of the
speciﬁc characteristics of the SZ monocyte signature,
since our study group of SZ patients was not con-
trolled for this variable (the BD patients were, see
Table 1).
Another limitation is that in our experimental de-
sign we made a selection of aberrantly expressed
genes by selecting, in whole genome analysis, only
highly over- and under-expressed genes (y3.5-fold),
which were clearly involved in inﬂammation and in-
ﬂammatory processes. Although this approach proved
to be fruitful in detecting the three ﬁngerprint patterns
described here (which also made a distinction between
BD and SZ possible), we may have missed important
causal genes for the inﬂammatory set-points, since our
assumption that the sheer expression level of genes is
important for the inﬂammatory state, is naive. Clearly,
further studies of additional genes that are less ab-
errantly expressed but are critically involved in in-
ﬂammation and/or have previously been described as
aberrant in psychiatric disorders are clearly needed to
see whether they are essential components of the in-
ﬂammatory monocyte gene ﬁngerprints.
The criteria used in psychiatry for validating noso-
logical categories have usually been restricted to clini-
cal features, outcome and family history (Craddock
& Owen, 2007). Kraepelin used these tools in for-
mulating his ideas, leading to his dichotomous classi-
ﬁcation between SZ and BD. Given that the main goal
of modern psychiatry is to provide eﬀective treatment,
the view has been expressed that the ultimate vali-
dator for a diagnostic system must be treatment re-
sponse based on a detailed knowledge of pathogenesis
(Owen & Craddock, 2009).
Our study, using powerful new research genomic
tools, precisely provides such new immune biological
validators, which probably not only play a role in
the immune pathogenesis of SZ and BD but are also
potential treatment targets. There are several reports
indicating that pharmacological interferences with
some of the up-regulated inﬂammatory signature
genes found, i.e. interference with PTGS2/COX-2,
PDE4B and TNF, may alleviate signs and symptoms of
SZ and depression (Akhondzadeh et al. 2007 ; Martina
et al. 2006 ; Muller et al. 2004, 2006; Myint et al. 2007 ;
Nery et al. 2008 ; Tyring et al. 2006 ; Zhu et al. 2001) and
it can thus be envisaged that in particular patients
positive for monocyte cluster 1 genes would beneﬁt
from treatment with COX-2, PDE4 and TNF inhibitors.
In conclusion, we here describe the ﬁrst steps in an
immune molecular dissecting approach on inﬂamma-
tory monocytes, which has already led to the identiﬁ-
cation of three coherent sets of putative immune
biomarker genes, opening new avenues for nosologi-
cal distinctions in psychiatric disease based on in-
ﬂammation. Our approach could also lead to putative
sub-classiﬁcation of patients with psychotic or BD,
who could possibly beneﬁt from adjunctive anti-
inﬂammatory treatment targeting important ﬁnger-
print genes.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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